About company
Quimatryx develops new drugs against epigenetic targets. Their main goal is the development of new selective inhibitors of HDAC6, a epigenetic target related with several diseases, such as cancer, central nervous system diseases or autoimmune disorders.
- Unknown
- Unknown
- Unknown
- quimatryx.com/index.php/en/
- Not verified company
